E. Maartense

发表

Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.

J Hermans, E. Schuuring, D. de Jong, 1998, Blood.

Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?

S. Jansen, A. Stiggelbout, M. Nooij, 2001, British Journal of Cancer.

Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.

H. Putter, C. Seynaeve, J. Nortier, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05)

H. Putter, E. Rutgers, J. Nortier, 2017 .

The insulin-like growth factor-system in a patient with diffuse large B-cell non-Hodgkin's lymphoma and lactic acidosis

J. van Doorn, E. Maartense, D. Hoogwerf, 2013, Annals of clinical biochemistry.

Cryptosporidiosis leading to an unsuspected diagnosis of AIDS.

F. Eulderink, E. Maartense, R. Vreede, 2004, The Netherlands journal of medicine.

Abstract S1-04: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

H. Putter, J. Nortier, J. Kroep, 2017 .

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

H. Putter, E. Rutgers, E. Rutgers, 2018, Journal of the National Cancer Institute.

Pulmonary alveolar proteinosis: a complication in patients with hematologic malignancy.

E. Maartense, R. V. van Rossem, J. M. Nijhuis-Heddes, 2000, The Netherlands journal of medicine.

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

H. Putter, P. Neven, H. Gelderblom, 2015, Breast Cancer Research and Treatment.

Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study

W. J. Mulder, E. Maartense, H. Schouten, 2015, Annals of Hematology.

Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly.

E. Giltay, S. le Cessie, P. Ypma, 2016, Acta oncologica.

Clinical Relevance of BCL 2 , BCL 6 , and MYC Rearrangements in Diffuse Large B-Cell Lymphoma

D. Jong, E. Schuuring, J. Hermans, 1998 .

Non-Hodgkin's lymphoma in the elderly

E. Noordijk, H. Kluin-Nelemans, E. Maartense, 2003, Annals of Hematology.

Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands.

E. Noordijk, J. Hermans, P. Kluin, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Pulmonary coccidioidomycosis: import illness and the importance of travel history.

E. Posthuma, E. Maartense, R. Vreede, 2009, The Netherlands journal of medicine.

Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy.

E. Giltay, S. le Cessie, J. Nortier, 2013, Journal of geriatric oncology.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

S. Loibl, V. Nekljudova, Marcus Schmidt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.

W. Scheithauer, T. Hickish, J. Tabernero, 2013 .

Lemierre's syndrome. Sepsis complicating an anaerobic oropharyngeal infection.

A. D. de Vos, E. Maartense, E. V. van Elzakker, 2001, The Netherlands journal of medicine.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

A. V. van Kuilenburg, J. Maring, E. Gross, 2010, Human Genetics.

High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.

H. Putter, J. Nortier, E. Kranenbarg, 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).

H. Putter, J. Nortier, J. Kroep, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.

S. Loibl, N. Harbeck, V. Nekljudova, 2011, European journal of cancer.

S. Cessie, S. le Cessie, E. Noordijk, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study.

C. Seynaeve, J. Nortier, B. V. van Munster, 2013, Breast.

Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy.

S. Cessie, E. Giltay, S. le Cessie, 2006, Critical reviews in oncology/hematology.

Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma

E. Giltay, S. le Cessie, P. Ypma, 2015, Leukemia & lymphoma.

Comorbidity and treatment decision-making in elderly non-Hodgkin's lymphoma patients: a survey among haematologists.

W. J. Mulder, E. Maartense, H. Schouten, 2014, The Netherlands journal of medicine.

Improved survival for patients with large B-cell lymphoma after introduction of rituximab.

E. Posthuma, E. Maartense, E. Rodenburg, 2009, The Netherlands journal of medicine.

Haemophagocytic syndrome and Hodgkin’s disease variant of Richter’s syndrome after fludarabine for CLL

L. Chaker, E. Maartense, F. Bot, 2010, European journal of haematology.

Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy.

E. Giltay, S. le Cessie, J. Nortier, 2013, Breast.

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014, Breast.

Lack of Prognostic Significance of BCL2 and p53 Protein Overexpression in Elderly Patients with Diffuse Large B-cell Non-Hodgkin's Lymphoma: Results from a Population-based Non-Hodgkin's Lymphoma Registry

S. le Cessie, S. Snijder, P. Kluin, 2004, Leukemia & lymphoma.

Omission of surgery in elderly patients with early stage breast cancer.

B. V. van Munster, S. D. de Rooij, E. Bastiaannet, 2013, European journal of cancer.

Abstract P2-09-08: Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)

H. Putter, J. Nortier, J. Kroep, 2017 .

Non-Hodgkin's lymphoma in the elderly. A review with emphasis on elderly patients, geriatric assessment, and future perspectives.

E. Noordijk, H. Kluin-Nelemans, E. Maartense, 2003, Annals of Hematology.

Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly

E. Giltay, S. le Cessie, P. Ypma, 2015, Acta oncologica.

Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer.

H. Putter, P. Neven, H. Guchelaar, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014 .

502PDMOSAIC STUDY: ACTUALIZATION OF OVERALL SURVIVAL (OS) WITH 10 YEARS FOLLOW UP AND EVALUATION OF BRAF. BY GERCOR AND MOSAIC INVESTIGATORS.

W. Scheithauer, T. Hickish, A. Duval, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer

E. Smets, A. Stiggelbout, C. Punt, 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

Different age limits for elderly patients with indolent and aggressive non‐Hodgkin lymphoma and the role of relative survival with increasing age

E. Noordijk, S. le Cessie, H. Kluin-Nelemans, 2000, Cancer.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy.

S. Cessie, E. Maartense, B. Tanis, 2013, Breast.

J. Nortier, M. Los, A. Wymenga, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.